QCG
NKTR icon

Quadrant Capital Group’s Nektar Therapeutics NKTR Stock Holding History

Quadrant Capital Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27
Closed -$1K – 2815
2022
Q3 		$1K Buy
27
+3
+13% +$178 ﹤0.01% 2539
2022
Q2 		$1K Sell
24
-214
-90% -$13.5K ﹤0.01% 2410
2022
Q1 		$19K Buy
238
+167
+235% +$24.7K ﹤0.01% 1362
2021
Q4 		$14K Buy
71
+55
+344% +$11.9K ﹤0.01% 1475
2021
Q3 		$4K Buy
16
+6
+60% +$1.44K ﹤0.01% 1951
2021
Q2 		$3K Hold
10
– – ﹤0.01% 2016
2021
Q1 		$3K Buy
10
+2
+25% +$622 ﹤0.01% 1965
2020
Q4 		$2K Sell
8
-12
-60% -$3.1K ﹤0.01% 1971
2020
Q3 		$5K Sell
20
-5
-20% -$1.57K ﹤0.01% 1552
2020
Q2 		$9K Sell
25
-70
-74% -$21.8K ﹤0.01% 1380
2020
Q1 		$24K Sell
95
-3
-3% -$928 ﹤0.01% 1207
2019
Q4 		$28K Buy
98
+11
+13% +$3.19K ﹤0.01% 1597
2019
Q3 		$22K Sell
87
-46
-35% -$16.9K ﹤0.01% 1564
2019
Q2 		$69K Buy
133
+121
+1,008% +$60.7K 0.01% 1058
2019
Q1 		$5K Hold
12
– – ﹤0.01% 1877
2018
Q4 		$4K Buy
12
+1
+9% +$604 ﹤0.01% 1726
2018
Q3 		$9K Sell
11
-11
-50% -$9.39K ﹤0.01% 1340
2018
Q2 		$14K Sell
22
-5
-19% -$5.76K ﹤0.01% 1122
2018
Q1 		$40K Buy
27
+14
+108% +$18K 0.01% 705
2017
Q4 		$11K Hold
13
– – ﹤0.01% 1142
2017
Q3 		$4K Buy
13
+6
+86% +$1.88K ﹤0.01% 1549
2017
Q2 		$0 Hold
7
– – ﹤0.01% 1992
2017
Q1 		$2K Hold
7
– – ﹤0.01% 1633
2016
Q4 		$1K Sell
7
-1
-13% -$203 ﹤0.01% 1749
2016
Q3 		$1K Hold
8
– – ﹤0.01% 1731
2016
Q2 		$1K Hold
8
– – ﹤0.01% 1705
2016
Q1 		$1K Sell
8
-16
-67% -$3.07K ﹤0.01% 1555
2015
Q4 		$6K Buy
+24
New +$4.93K ﹤0.01% 995

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Quadrant Capital Group's NKTR Position: Q4 2022 in Review

Quadrant Capital Group sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 27 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in NKTR in Q4 2015 and held it in 28 quarters. The position peaked at $69K in Q2 2019. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • Quadrant Capital Group reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 27 Nektar Therapeutics shares in Q4 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Nektar Therapeutics in Q4 2015 and held it in 28 quarters.
  • Quadrant Capital Group's Nektar Therapeutics position peaked at $69K in Q2 2019.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.